We have ENTA's current EV of $300m ($650m cap - cash on hand & 2015 milestones). So the street, using ENTAs current cap, doesn't expect ABBV to do $8b HCV sales throughout the entire life of v-pak. And they're also attributing 0 value to the next gen program or anything else in ENTA's pipeline. Seems a bit crazy...
On another note, does anyone have any thoughts/ideas on what ENTA should do with its horde?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.